ONCORUS Misses Earnings Expectations by $0.48 per Share

☀️Trending News

Oncorus ($NASDAQ:ONCR), an immuno-oncology company focused on leveraging the power of the immune system to fight cancer, recently reported its GAAP earnings per share of -$1.18, missing expectations by $0.48 per share. Despite its strong history of innovation in the field of immuno-oncology, Oncorus was unable to meet market estimates this quarter. The disappointment came as a surprise to many investors, as Oncorus had been expected to continue its positive momentum from previous quarters.

However, despite this setback, the company is still well-positioned and has the potential to exceed expectations in the future. With a broad pipeline of promising treatments and a strong commitment to scientific excellence, Oncorus remains one of the most promising players in the field of immuno-oncology.

Earnings

In the earnings report of ONCORUS‘s FY2022 Q4 ending December 31 2022, the company failed to meet analyst expectations with a net loss of $20.93M USD. This was a sharp decline from their total revenue of 0.0M USD in the same period – a difference of $0.48 per share. Over the past three years, ONCORUS has seen a steady decrease in total revenue from 0.0M USD to 0.0M USD. This has been a major challenge for the company as they continue to seek ways to improve their financial performance.

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Oncorus. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Oncorus. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Oncorus. More…

Key Ratios Snapshot

Some of the financial key ratios for Oncorus are shown below. More…

Stock Price

On Monday, shares of ONCORUS opened at $0.3 and closed at $0.3, up 2.1% from its last closing price of 0.3. However, the company missed analysts’ earnings expectations by $0.48 per share, surprising investors and sending the stock down in after-hours trading. Investors were hoping for better earnings from the company, which has struggled to keep up with the competition and has seen its margins decline in recent quarters. The disappointing earnings results will likely put pressure on the company to improve performance and maximize profitability in the coming quarters. Live Quote…

Analysis

At GoodWhale, we have conducted an analysis of ONCORUS‘s financials. We have concluded that ONCORUS is a medium risk investment in terms of financial and business aspects, based on our Risk Rating. After closely examining the income sheet, balance sheet, and cashflow statement, we have detected three risk warnings that potential investors should be aware of. To find out more information about these risk warnings, register with us to gain access to our innovative financial analysis. More…

Peers

With a commitment to creating life-saving treatments, Oncorus is revolutionizing cancer therapy with novel therapies that stimulate the patient’s own immune system to fight tumors. Oncorus is competing against other biotech companies such as Coya Therapeutics Inc, Metacrine Inc, and Outlook Therapeutics Inc, who are also making great strides in the cancer treatment field.

– Coya Therapeutics Inc ($NASDAQ:COYA)

Coya Therapeutics Inc is a biopharmaceutical company focused on the development of novel therapeutics to treat autoimmune diseases and cancer. It has a market cap of 45.46M as of 2023 and a Return on Equity of -177.41%. This indicates that Coya Therapeutics Inc has been struggling to generate profit or provide value to its shareholders, reflecting the difficulty of the drug development process. Despite this, the market cap indicates that investors still have faith in the company’s potential to develop and commercialize successful treatments.

– Metacrine Inc ($OTCPK:MTCR)

Metacrine Inc is a biopharmaceutical company based in San Diego, California. The company focuses on discovering and developing innovative treatments for metabolic and liver diseases. As of 2023, Metacrine Inc has a market cap of 23.89M. This value is indicative of the company’s ability to generate profits and grow its business, which can be further seen through its Return on Equity (ROE) of -57.69%. Despite this negative return, the company has still managed to remain competitive in its industry, suggesting that there may be potential for improvement in the near future.

– Outlook Therapeutics Inc ($NASDAQ:OTLK)

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative ophthalmic products. The company’s market cap as of 2023, is 411.95M and its Return on Equity (ROE) is -262.08%. Market capitalization is a measure of a company’s value in the stock market – the higher the market cap, the greater the value of the company. On the other hand, Return on Equity measures how much profit a company generates for every dollar of equity it holds. Outlook Therapeutics Inc’s negative return on equity indicates that it is not generating profits from the funds invested by shareholders.

Summary

Investors analyzing Oncorus should take into account the company’s GAAP earnings per share (EPS) of -$1.18, which missed analysts’ expectations by $0.48. Although this is a negative sign, it is important to consider the company’s longer-term financial performance as well. Analysts should look at cash flow from operating activities, total assets, and other metrics to get an overall idea of Oncorus’s financial health and sustainability.

An analysis of the company’s competitive landscape, its product offerings, and the markets in which it operates should also be considered to assess the business’s future prospects. Ultimately, investors must weigh the risks and potential rewards of Oncorus before making any decisions.